



The Commonwealth of Massachusetts
Executive Office of Health and Human Services
Office of Medicaid
One Ashburton Place, Room 1109
Boston, Massachusetts 02108



CHARLES D. BAKER
Governor

KARYN E. POLITO
Lieutenant Governor

MARYLOU SUDDERS
Secretary

AMANDA CASSEL KRAFT
Assistant Secretary for
MassHealth

www.mass.gov/eohhs

October 5, 2022

Chair Michael J. Rodrigues
Senate Committee on Ways and Means
State House, Room 212
Boston, MA 02133

Chair Aaron Michlewitz
House Committee on Ways and Means
State House, Room 243
Boston, MA 02133

Chair Cindy F. Friedman
Joint Committee on Health Care Financing
State House, Room 416A
Boston, MA 02133

Chair John Lawn, Jr.
Joint Committee on Health Care Financing
State House, Room 236
Boston, MA 02133

Dear Chairs Rodrigues, Michlewitz, Friedman, and Lawn:

Chapter 126 of the Acts of 2022 line item 4000-0300 requires the Executive Office of Health and Human Services to submit a quarterly report including the projected total costs for the next fiscal year of pharmaceutical pipeline drugs identified by the executive office and expected to be made available for utilization within a 12-month period.

The Executive Office of Health and Human Services has identified 109 new pipeline market entries from 98 manufacturers expected to be made available for utilization between July 1, 2022, and June 30, 2023. The estimated spend on the expected utilization of these products for all MassHealth members (including members enrolled with managed care) is approximately \$20.4M for the same time-period. The prior quarterly report estimated an increased spend of \$19.5M based on the addition of 122 new pipeline market entries, from 101 manufacturers. The change from the last quarterly report was largely driven by a projected increase in utilization for some pipeline market entries and the FDA decision timeline shifting for a number of drugs.

I am grateful for your continued support of the MassHealth program. Please feel free to contact Camille Pearson at Camille.pearson@mass.gov should you have any questions about this report.

Sincerely,

Amanda Cassel Kraft

cc: Marylou Sudders